Green Valley Investors LLC Decreases Holdings in Gilead Sciences (GILD)

Green Valley Investors LLC cut its holdings in shares of Gilead Sciences (NASDAQ:GILD) by 7.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 210,081 shares of the biopharmaceutical company’s stock after selling 16,624 shares during the quarter. Gilead Sciences accounts for approximately 0.7% of Green Valley Investors LLC’s holdings, making the stock its 28th biggest holding. Green Valley Investors LLC’s holdings in Gilead Sciences were worth $15,050,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Rowland & Co. Investment Counsel ADV purchased a new position in shares of Gilead Sciences in the second quarter worth $153,000. Stonebridge Capital Advisors LLC increased its stake in shares of Gilead Sciences by 260.6% in the second quarter. Stonebridge Capital Advisors LLC now owns 73,943 shares of the biopharmaceutical company’s stock worth $5,234,000 after buying an additional 53,440 shares during the period. Scotia Capital Inc. increased its stake in shares of Gilead Sciences by 9.8% in the second quarter. Scotia Capital Inc. now owns 146,411 shares of the biopharmaceutical company’s stock worth $10,362,000 after buying an additional 13,078 shares during the period. Linscomb & Williams Inc. increased its stake in shares of Gilead Sciences by 10.1% in the second quarter. Linscomb & Williams Inc. now owns 5,806 shares of the biopharmaceutical company’s stock worth $411,000 after buying an additional 531 shares during the period. Finally, Chiron Investment Management LLC increased its stake in shares of Gilead Sciences by 42.9% in the second quarter. Chiron Investment Management LLC now owns 266,500 shares of the biopharmaceutical company’s stock worth $18,863,000 after buying an additional 80,000 shares during the period. 78.30% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts recently commented on GILD shares. BidaskClub raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Thursday, December 14th. Credit Suisse Group cut shares of Gilead Sciences from an “outperform” rating to a “neutral” rating and lifted their price target for the company from $74.35 to $80.00 in a report on Wednesday, December 20th. Oppenheimer reiterated a “hold” rating on shares of Gilead Sciences in a report on Thursday, December 21st. Zacks Investment Research cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, December 27th. Finally, BMO Capital Markets reiterated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, January 3rd. Two research analysts have rated the stock with a sell rating, nine have given a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $88.61.



In other news, EVP James R. Meyers sold 100,000 shares of the business’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $80.24, for a total transaction of $8,024,000.00. Following the sale, the executive vice president now owns 102,715 shares in the company, valued at approximately $8,241,851.60. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director John Francis Cogan sold 5,833 shares of the business’s stock in a transaction on Friday, April 6th. The shares were sold at an average price of $74.47, for a total transaction of $434,383.51. Following the sale, the director now owns 58,452 shares in the company, valued at approximately $4,352,920.44. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 402,767 shares of company stock worth $31,911,485. Company insiders own 1.30% of the company’s stock.

Shares of GILD stock opened at $75.29 on Friday. Gilead Sciences has a 12 month low of $63.76 and a 12 month high of $89.54. The firm has a market cap of $97,814.82, a PE ratio of 8.80, a price-to-earnings-growth ratio of -1.72 and a beta of 1.19. The company has a current ratio of 2.74, a quick ratio of 2.67 and a debt-to-equity ratio of 1.53.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, beating the Zacks’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The firm had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $5.71 billion. During the same quarter in the previous year, the business posted $2.70 EPS. The company’s quarterly revenue was down 18.7% on a year-over-year basis. analysts expect that Gilead Sciences will post 6.21 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 29th. Stockholders of record on Friday, March 16th were issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.03%. The ex-dividend date was Thursday, March 15th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s payout ratio is 26.64%.

WARNING: “Green Valley Investors LLC Decreases Holdings in Gilead Sciences (GILD)” was first posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://dakotafinancialnews.com/2018/04/13/green-valley-investors-llc-decreases-holdings-in-gilead-sciences-gild.html.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply